CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)

DRUG3 trials

Sponsors

Genentech, Inc., The Lymphoma Academic Research Organisation, Chipscreen Biosciences, Ltd.

Conditions

Lymphoma, T-Cell, PeripheralMarginal Zone LymphomaNon-Hodgkin's Lymphoma

Phase 3

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

CompletedNCT00719472

Genentech, Inc.Non-Hodgkin's Lymphoma

Start: 2008-07-31End: 2011-05-31Updated: 2017-05-15

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

RecruitingNCT06006117

The Lymphoma Academic Research OrganisationMarginal Zone Lymphoma

Start: 2023-09-05End: 2032-09-30Target: 260Updated: 2025-12-19

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

RecruitingNCT06947967

Chipscreen Biosciences, Ltd.Lymphoma, T-Cell, Peripheral

Start: 2025-08-12End: 2032-12-31Target: 224Updated: 2025-09-15